Skip to main content
Equibles

CAPTRUST FINANCIAL ADVISORS

Position in HUMA — Humacyte, Inc.

CIK 1512024 RALEIGH, NC
Back to HUMA Full portfolio

Position in HUMA

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$23,293
+$2,374 QoQ
Shares Held
29,864
-13.3% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#82
of 163 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 19% Shared 0% None 81%

Common Shares in HUMA Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CAPTRUST FINANCIAL ADVISORS holds $169,003,876 across 125 Biotechnology names. HUMA ranks #110 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 REGN
Regeneron Pharmaceuticals, Inc.
 36,464 $22,736,762
2 RPRX
Royalty Pharma plc
 337,298 $18,912,298
3 VRTX
Vertex Pharmaceuticals Inc / Ma
 35,471 $17,619,509
4 EXEL
Exelixis, Inc.
 303,042 $16,488,515
5 LGND
Ligand Pharmaceuticals Inc
 34,607 $10,938,926
6 HALO
Halozyme Therapeutics, Inc.
 125,946 $9,857,793
7 CELC
Celcuity Inc.
 71,445 $7,474,575
8 INCY
Incyte Corp
 50,301 $5,702,121

All Filings in HUMA

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $23,293 29,864
2026-03-31 $20,919 34,464